1
|
Li H, Chen C, Yao H, Li X, Yang N, Qiao J, Xu K, Zeng L. Identification of Suitable Reference Genes for mRNA Studies in Bone Marrow in a Mouse Model of Hematopoietic Stem Cell Transplantation. Transplant Proc 2017; 48:2826-2832. [PMID: 27788825 DOI: 10.1016/j.transproceed.2016.07.028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Accepted: 07/14/2016] [Indexed: 11/24/2022]
Abstract
BACKGROUND Bone marrow micro-environment changes during hematopoietic stem cell transplantation (HSCT) with subsequent alteration of genes expression. Quantitative polymerase chain reaction (q-PCR) is a reliable and reproducible technique for the analysis of gene expression. To obtain more accurate results, it is essential to find a reference during HSCT. However, which gene is suitable during HSCT remains unclear. This study aimed to identify suitable reference genes for mRNA studies in bone marrow after HSCT. METHODS C57BL/6 mice were treated with either total body irradiation (group T) or busulfan/cyclophosphamide (BU/CY) (group B) followed by infusion of bone marrow cells. Normal mice without treatments were served as a control. All samples (group T + group B + control) were defined as group G. On days 7, 14, and 21 after transplantation, transcription levels of 7 candidate genes, ACTB, B2M, GAPDH, HMBS, HPRT, SDHA, and YWHAZ, in bone marrow cells were measured by use of real-time quantitative PCR. The expression stability of these 7 candidate reference genes were analyzed by 2 statistical software programs, GeNorm and NormFinder. RESULTS Our results showed that ACTB displayed the highest expression in group G, with lowest expression of PSDHA in group T and HPRT in groups B and G. Analysis of expression stability by use of GeNorm or NormFinder demonstrated that expression of B2M in bone marrow were much more stable during HSCT, compared with other candidate genes including commonly used reference genes GAPDH and ACTB. CONCLUSIONS ACTB could be used as a suitable reference gene for mRNA studies in bone marrow after HSCT.
Collapse
Affiliation(s)
- H Li
- Department of Clinical Laboratory, the Affiliated Hospital of Xuzhou Medical College, Xuzhou, China
| | - C Chen
- Blood Diseases Institute, Xuzhou Medical College, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China
| | - H Yao
- Blood Diseases Institute, Xuzhou Medical College, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China
| | - X Li
- Blood Diseases Institute, Xuzhou Medical College, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China
| | - N Yang
- Blood Diseases Institute, Xuzhou Medical College, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China
| | - J Qiao
- Blood Diseases Institute, Xuzhou Medical College, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China; Department of Hematology, the Affiliated Hospital of Xuzhou Medical College, Xuzhou, China
| | - K Xu
- Blood Diseases Institute, Xuzhou Medical College, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China; Department of Hematology, the Affiliated Hospital of Xuzhou Medical College, Xuzhou, China.
| | - L Zeng
- Blood Diseases Institute, Xuzhou Medical College, Xuzhou, China; Key Laboratory of Bone Marrow Stem Cell, Jiangsu Province, Xuzhou, China; Department of Hematology, the Affiliated Hospital of Xuzhou Medical College, Xuzhou, China.
| |
Collapse
|
2
|
Trends and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant for Multiple Myeloma at Mayo Clinic. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2015; 15:349-357.e2. [DOI: 10.1016/j.clml.2015.03.016] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Revised: 03/23/2015] [Accepted: 03/26/2015] [Indexed: 11/23/2022]
|
3
|
Qian L, Wu Z, Shen J. Advances in the treatment of acute graft-versus-host disease. J Cell Mol Med 2013; 17:966-75. [PMID: 23802653 PMCID: PMC3780546 DOI: 10.1111/jcmm.12093] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2013] [Accepted: 05/15/2013] [Indexed: 12/13/2022] Open
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) has been widely used for the treatment of hematologic malignant and non-malignant hematologic diseases and other diseases. However, acute graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic transplantation. Acute GVHD may occur in 30% of transplant recipients, which is a syndrome of erythematous skin eruption, cholestatic liver disease and intestinal dysfunction, resulting from the activation of donor T lymphocytes by host antigen-presenting cells, resulting in an immune-mediated inflammatory response. Recent scientific advances in the understanding of the pathogenesis involved in the development of acute GVHD and clinical investigation have provided more effective therapeutic strategies for acute GVHD. This review focuses on major scientific and clinical advances in the treatment of acute GVHD.
Collapse
Affiliation(s)
- Liren Qian
- Department of Haematology, Navy General Hospital, Beijing, China.
| | | | | |
Collapse
|
4
|
Mohamed SYA, Fadhil I, Hamladji RM, Ali Hamidieh A, Fahmy O, Ladeb S, Alimoghaddam K, Elhaddad A, Ahmed Nacer R, Alsharif F, Rasheed W, Jahani M, Mousavi SA, Alseraihy A, Abdel-Rahman F, Al Jefri A, Hussein AA, Alabdulaaly A, Ibrahim A, Bekadja MA, Abboud M, Ahmed P, Dennison D, Bakr M, Benchekroun S, Hussain F, Othman TB, Aljurf M, Ghavamzadeh A. Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: Report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group. Hematol Oncol Stem Cell Ther 2011; 4:81-93. [DOI: 10.5144/1658-3876.2011.81] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
5
|
Sanchez CJ, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello RT. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother 2011; 60:1-13. [PMID: 20697893 PMCID: PMC11029698 DOI: 10.1007/s00262-010-0898-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2010] [Accepted: 07/24/2010] [Indexed: 01/01/2023]
Abstract
Despite recent progress in the therapeutic approach of malignant haemopathies, their prognoses remain frequently poor. Immunotherapy offers an alternative of great interest in this context but defect or abnormal expression of human leukocyte antigens (HLA), frequently observed in cancer cells, limits its efficiency. Natural killer (NK) cells, which are able to kill target cells in a HLA-independent way, represent a novel tool in the treatment of haematological malignancies. Abnormal NK cytolytic function is observed in all the haematological malignancies studied, such as acute leukaemia, myelodysplastic syndromes or chronic myeloid/lymphoid leukaemia. Several mechanisms are involved in the alterations of NK cytotoxicity: decreased expression of activating receptors, increased expression of inhibitory receptors or defective expression of NK ligands on target cells. Further studies are needed to identify how each type of haematological malignancy escapes from the innate immune response. Attempts to increase the expression of activating receptors, to counteract inhibitory receptors expression, or to increase NK cell cytotoxic capacities could overcome tumour escape from innate immunity. These therapies are based on monoclonal antibodies or culture of NK cells in presence of cytokines or dendritic cells. Moreover, many novel drugs used in haematological malignancies [tyrosine kinase inhibitors, IMIDs(®), proteasome inhibitors, demethylating agents, histone deacetylase inhibitors (HDACis), histamine dihydrochloride] display interesting immunomodulatory properties that affect NK cells. These data suggest that combined modalities associating cytotoxic drugs with innate immunity modulators may represent a major breakthrough in tumour eradication.
Collapse
Affiliation(s)
- C. J. Sanchez
- Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, Marseille, France
- Université de la Méditerranée, Marseille, France
- U928 Inserm, TAGC, Marseille, France
- Laboratoire d’Hématologie, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - T. Le Treut
- U928 Inserm, TAGC, Marseille, France
- Laboratoire d’Hématologie, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - A. Boehrer
- Laboratoire d’Hématologie, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - B. Knoblauch
- Laboratoire d’Hématologie, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - J. Imbert
- U928 Inserm, TAGC, Marseille, France
| | - D. Olive
- Université de la Méditerranée, Marseille, France
- Centre de Recherche en Cancérologie de Marseille, UMR891 Inserm, Marseille, France
| | - R. T. Costello
- Université de la Méditerranée, Marseille, France
- U928 Inserm, TAGC, Marseille, France
- Laboratoire d’Hématologie, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, Marseille, France
- Service d’Hématologie, Hôpital La Conception, Assistance Publique des Hôpitaux de Marseille, 147 boulevard Baille, 13005 Marseille, France
| |
Collapse
|
6
|
Nakasone H, Kanda Y, Ueda T, Matsumoto K, Shimizu N, Minami J, Sakai R, Hagihara M, Yokota A, Oshima K, Tsukada Y, Tachibana T, Nakaseko C, Fujisawa S, Yano S, Fujita H, Takahashi S, Kanamori H, Okamoto S. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma. Am J Hematol 2009; 84:809-14. [PMID: 19862826 DOI: 10.1002/ajh.21552] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The combination of cyclophosphamide and granulocyte-colony stimulating factor (G-CSF) has widely been used to mobilize hematopoietic stem cells (HSCs) for autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Recently, however, alternative approaches such as G-CSF alone or etoposide followed by G-CSF have been investigated. We, therefore, retrospectively analyzed the effects of these mobilization methods on collection yield and disease outcome in ASCT for MM. We reviewed 146 MM patients from whom we intended to collect stem cells. For mobilization, 67, 58, and 21 patients received cyclophosphamide and G-CSF, etoposide and G-CSF, and G-CSF alone (including nonmyelosuppressive chemotherapy followed by G-CSF), respectively. Among them, 136 achieved the target number of HSCs (at least 2 x 10(6)/kg). Lower creatinine and higher albumin levels at diagnosis were significantly associated with successful yield. A lower number of infused HSCs, use of the etoposide for mobilization and high ISS were associated with delayed hematopoietic recovery. The mobilization methods did not significantly affect either the successful collection of more than 2 x 10(6) CD34-positive cells/kg or PFS after ASCT. G-CSF alone was sufficient for stem cell mobilization for a single ASCT. The optimal approach to collect HSCs in MM remains to be elucidated.
Collapse
Affiliation(s)
- Hideki Nakasone
- Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Saitama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Basak GW, Carrier E. The search for multiple myeloma stem cells: the long and winding road. Biol Blood Marrow Transplant 2009; 16:587-94. [PMID: 19895894 DOI: 10.1016/j.bbmt.2009.10.024] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2009] [Accepted: 10/23/2009] [Indexed: 11/30/2022]
Abstract
Recent years have brought significant breakthroughs in the understanding of tumor biology, related to discovery of cancer stem cells (CSCs) in acute myelogenous leukemia as well as in a number of solid tumors. This finding revealed that not all tumor cells are able to divide indefinitely, and that the bulk of tumor cells are expanded because of divisions and differentiation of CSC fraction. Although the CSCs identified in acute leukemia have a phenotype of early hematopoietic progenitors, it seems that CSCs in multiple myeloma (MM) may resemble the memory B cell fraction. Previous studies in patients with MM have documented the existence of cells without plasma cell characteristics expressing MM-type immunoglobulin genes--so-called "clonotypic" B cells. These cells have been characterized functionally and phenotypically as chemoresistant recirculating B cells. They have been found to self-renew and to be capable of initiating MM growth in immunocompromised animals. Controversy exists as to whether these cells truly belong to an MM clone, however; they may represent only the remaining clones of premalignant B cells. The identification of MM stem cells responsible for the recurrence of MM is of primary importance in designing targeted therapies to definitely cure this disease. This article summarizes the current state of knowledge on these hypothetical "MM stem cells."
Collapse
Affiliation(s)
- Grzegorz Wladyslaw Basak
- Rebecca and John Moore's Cancer Center, University of California San Diego, San Diego, California, USA
| | | |
Collapse
|
8
|
Giglio G, Romito S, Carrozza F, Musacchio M, Antuzzi G, Gigli R, Magri M, Bavaro P, Di Bartolomeo P, Dell'Isola M, Accorsi P. Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2. Int J Hematol 2009; 90:81-86. [PMID: 19529980 DOI: 10.1007/s12185-009-0354-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2009] [Revised: 05/01/2009] [Accepted: 05/15/2009] [Indexed: 12/22/2022]
Abstract
Autologous stem cell transplantation is considered the best post-induction therapy for multiple myeloma (MM). Therefore, therapy for myeloma should be chosen not only on the basis of efficacy, but also taking into account their impact on the hematopoietic stem cell compartment. We describe the case of a MM patient in which a successful mobilization of peripheral stem cells was obtained with bortezomib, cyclophosphamide and G-CSF, after two failed attempts in the framework of Total Therapy 2. The patient underwent an autologous transplantation, showing a rapid and complete post-transplant hematological recovery. Our experience suggests that bortezomib is an effective anti-myeloma agent without negative impact on stem cell mobilization, even in patients with a previous history of failed harvest.
Collapse
Affiliation(s)
- Gianfranco Giglio
- Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy.
| | - Sante Romito
- Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy
| | - Francesco Carrozza
- Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy
| | - Michela Musacchio
- Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy
| | - Giustino Antuzzi
- Oncology Regional Department, Oncology and Hematology Units, "A.Cardarelli" Hospital, C.da Tappino, 86100, Campobasso, Italy
| | - Rosanna Gigli
- Laboratory Medicine Unit, "A.Cardarelli" Hospital, Campobasso, Italy
| | - Marilù Magri
- Laboratory Medicine Unit, "A.Cardarelli" Hospital, Campobasso, Italy
| | - Pasqua Bavaro
- Department of Hematology, Hematological Intensive Care for Hematopoietic Transplantation Unit, Pescara Hospital, Pescara, Italy
| | - Paolo Di Bartolomeo
- Department of Hematology, Hematological Intensive Care for Hematopoietic Transplantation Unit, Pescara Hospital, Pescara, Italy
| | - Mario Dell'Isola
- Department of Transfusional Medicine, Apheresis Unit, Pescara Hospital, Pescara, Italy
| | - Patrizia Accorsi
- Department of Transfusional Medicine, Apheresis Unit, Pescara Hospital, Pescara, Italy
| |
Collapse
|
9
|
|
10
|
Affiliation(s)
- Francine Foss
- Medical Oncology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT 06520, USA.
| | | |
Collapse
|
11
|
Curioni-Fontecedro A, Knights AJ, Tinguely M, Nuber N, Schneider C, Thomson CW, von Boehmer L, Bossart W, Pahlich S, Gehring H, Moch H, Renner C, Knuth A, Zippelius A. MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia 2008; 22:1646-8. [PMID: 18323799 DOI: 10.1038/leu.2008.43] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
12
|
Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008; 22:998-1006. [PMID: 18288133 DOI: 10.1038/leu.2008.15] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Exploiting the antitumor effect of natural killer (NK) cells has regained interest in light of data from preclinical and clinical work on the potential of alloreactive NK cells. Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) represent the two most prevalent adult hematological malignancies in the western hemisphere. To evaluate the role of NK cells in the immune surveillance and their therapeutic potential for CLL and MM, tumor cell susceptibility to NK-mediated killing was investigated. Results show relative resistance of tumor cells from CLL as well as MM (73 and 70% of the patients, respectively) to NK-mediated killing. To gain insight into molecular mechanisms of this resistance, the expression of the tolerogenic HLA-G molecule in CLL and MM and its relevance to susceptibility to NK-mediated killing were investigated. HLA-G transcript was found in tumor cells from 89% (n=19) of CLL and 100% (n=9) of MM patients examined. HLA-G1 surface expression was observed in CLL and was very low or undetectable in MM. Notably, blocking of HLA-G1 with specific antibody on CLL samples increased their susceptibility to NK-mediated killing, demonstrating that HLA-G participates in protecting CLL cells from NK-mediated killing and may thus contribute to their immune escape in vivo.
Collapse
Affiliation(s)
- G Maki
- Section of Hematology and Bone Marrow Transplantation, Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA.
| | | | | | | | | | | | | |
Collapse
|
13
|
Current Awareness in Hematological Oncology. Hematol Oncol 2008. [DOI: 10.1002/hon.831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
14
|
Litzow MR. Is autologous progenitor cell mobilization getting any easier? Leuk Lymphoma 2007; 48:2304-5. [PMID: 18067002 DOI: 10.1080/10428190701671085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Mark R Litzow
- Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
| |
Collapse
|
15
|
Abstract
PURPOSE OF REVIEW Several novel therapies have been licensed for the treatment of myeloma in recent years. We summarize some of the trials leading to their approval and the current evidence for their clinical use. A number of promising agents undergoing phase I/II trial evaluation are also discussed. RECENT FINDINGS The immunomodulatory drugs, thalidomide and lenalidomide, and the proteasome inhibitor, bortezomib, have been shown to be effective agents, both alone and as part of combination regimens, for the treatment of myeloma. Studies are now focusing on the optimal sequencing of these drugs throughout the disease course, with a view to maximizing antitumor efficacy and minimizing overlapping toxicities. New protocols are increasingly based on preclinical evidence of synergy. The incorporation of these agents into transplant-based treatment protocols has improved outcomes. Other examples of novel agents undergoing assessment at present include arsenic trioxide, hsp90 inhibitors and histone deacetylase inhibitors. Future developments are likely to include individualized treatment plans based on patient-specific parameters including cytogenetic analysis and gene expression profiling. SUMMARY Thalidomide, lenalidomide and bortezomib can now be considered as standard options both as first-line agents and beyond for the treatment of myeloma, with respective combinations also emerging as valid choices for all stages of the disease.
Collapse
|